HRS - Hepatorenal Syndrome
PHASE 3 TREATMENT TRIAL
HRS MNK19013058
Title: A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)
Condition & Intervention: HRS: Terlipressin Acetate (IV, 1 mg by bolus injection q 6 hours)
PI: Landis
Site: HMC